Elena Ratner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5400120/publications.pdf

Version: 2024-02-01

59 papers	1,690 citations	279798 23 h-index	289244 40 g-index
59 all docs	59 docs citations	59 times ranked	2806 citing authors

#	Article	IF	Citations
1	Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. Journal of Clinical Oncology, 2018, 36, 2044-2051.	1.6	313
2	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelialâ€“mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12238-12243.	7.1	181
3	A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research, 2010, 70, 6509-6515.	0.9	135
4	Polymerase Îµ (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecologic Oncology, 2015, 138, 11-17.	1.4	68
5	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibodyâ€“Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. Molecular Cancer Therapeutics, 2016, 15, 1900-1909.	4.1	55
6	Polymerase Îµ (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology, 2017, 144, 146-152.	1.4	55
7	A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology, 2018, 149, 585-591.	1.4	53
8	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22730-22736.	7.1	52
9	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibodyâ€“Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clinical Cancer Research, 2017, 23, 5836-5845.	7.0	51
10	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 619-624.	7.1	49
11	Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	48
12	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecologic Oncology, 2017, 146, 179-186.	1.4	37
13	Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. Molecular Cancer Therapeutics, 2017, 16, 323-333.	4.1	34
14	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget, 2020, 11, 560-570.	1.8	32
15	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Scientific Reports, 2020, 10, 973.	3.3	31
16	Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo. Molecular Cancer Therapeutics, 2015, 14, 2519-2526.	4.1	30
17	Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. Frontiers in Oncology, 2020, 10, 118.	2.8	30
18	Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTEÂ®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Journal of Experimental and Clinical Cancer Research, 2015, 34, 123.	8.6	29

#	Article	IF	Citations
19	PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecologic Oncology, 2019, 155, 144-150.	1.4	28
20	A phase 2 evaluation of pembrolizumab for recurrent Lynchâ€like versus sporadic endometrial cancers with microsatellite instability. Cancer, 2022, 128, 1206-1218.	4.1	28
21	Clostridium perfringens enterotoxin <scp>C</scp>â€terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapyâ€resistant ovarian cancer. International Journal of Cancer, 2015, 137, 2618-2629.	5.1	27
22	Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic Oncology, 2015, 139, 112-117.	1.4	27
23	Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal of Cancer, 2016, 115, 303-311.	6.4	27
24	In Vitro and In Vivo Activity of IMGN853, an Antibodyâ€“Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Molecular Cancer Therapeutics, 2018, 17, 1003-1011.	4.1	25
25	Sacituzumab govitecan, an antibodyâ€drug conjugate targeting trophoblast cellâ€surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas inÂvitro and inÂvivo. Molecular Oncology, 2020, 14, 645-656.	4.6	20
26	Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecologic Oncology, 2017, 147, 145-152.	1.4	18
27	Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clinical Cancer Research, 2018, 24, 4845-4853.	7.0	18
28	Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines inÂvitro. American Journal of Obstetrics and Gynecology, 2016, 214, 99.e1-99.e8.	1.3	17
29	Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. Medical Oncology, 2017, 34, 91.	2.5	16
30	High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. Journal of Contemporary Brachytherapy, 2015, 1, 35-40.	0.9	14
31	Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer. Journal of Gynecologic Oncology, 2017, 28, e84.	2.2	14
32	Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. Reproductive Sciences, 2019, 26, 600-608.	2.5	14
33	Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. Gynecologic Oncology, 2021, 163, 93-99.	1.4	14
34	Results of COVID-minimal Surgical Pathway During Surge-phase of COVID-19 Pandemic. Annals of Surgery, 2020, 272, e316-e320.	4.2	14
35	PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. Gynecologic Oncology, 2019, 153, 158-164.	1.4	13
36	The use of QuikClot combat gauze in cervical and vaginal hemorrhage. Gynecologic Oncology Reports, 2017, 21, 114-116.	0.6	12

#	Article	IF	Citations
37	Financial toxicity in patients with gynecologic malignancies: a cross sectional study. Journal of Gynecologic Oncology, 2021, 32, e87.	2.2	10
38	Intraâ€•operative evaluation of prophylactic hysterectomy and salpingoâ€•oophorectomy specimens in hereditary gynaecological cancer syndromes. Histopathology, 2018, 73, 109-123.	2.9	9
39	A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer.. Journal of Clinical Oncology, 2018, 36, 5536-5536.	1.6	9
40	Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship. Human Pathology, 2021, 118, 1-8.	2.0	6
41	A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).. Journal of Clinical Oncology, 2021, 39, 5523-5523.	1.6	5
42	Randomised phase II trial of weekly ixabepiloneâ€‰Â±â€‰biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal of Cancer, 2022, 126, 1695-1703.	6.4	5
43	Benefits of a Multidisciplinary Womenâ€™s Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 143-149.	1.3	4
44	Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecologic Oncology, 2021, 163, 557-562.	1.4	4
45	Single application hybrid interstitial brachytherapy for cervical cancer: An institutional approach during the COVID-19 pandemic. Journal of Contemporary Brachytherapy, 2022, 14, 66-71.	0.9	4
46	Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. Gynecologic Oncology, 2020, 158, 769-775.	1.4	2
47	Riskâ€•stratifying clinicopathologic criteria for ovarian preservation in premenopausal women with early stage lowâ€•risk endometrial cancer. International Journal of Gynecology and Obstetrics, 2020, 150, 385-391.	2.3	1
48	Weekly ixabepilone with or without concurrent bevacizumab in the treatment of recurrent endometrial cancer.. Journal of Clinical Oncology, 2012, 30, e15526-e15526.	1.6	1
49	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression.. Journal of Clinical Oncology, 2017, 35, e14009-e14009.	1.6	1
50	Serum-based assay for adnexal mass risk of ovarian malignancy.. Journal of Clinical Oncology, 2021, 39, 5551-5551.	1.6	0
51	Abstract 911:In vitroandin vivoactivity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma. , 2021, , .		0
52	Targeting the upregulation of the AKT pathway and homologous recombination repair as a therapeutic strategy for epithelial ovarian cancer.. Journal of Clinical Oncology, 2012, 30, e13125-e13125.	1.6	0
53	Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC).. Journal of Clinical Oncology, 2012, 30, 5099-5099.	1.6	0
54	Demographics of uterine serous cancer (USC) patients: A single institutional experience.. Journal of Clinical Oncology, 2012, 30, e15581-e15581.	1.6	0

#	Article	IF	Citations
55	Evaluation of the diagnostic accuracy of cervical biopsy and determination of associated risk factors for positive margin status in recurrent cervical dysplasia after leep or conization.. Journal of Clinical Oncology, 2014, 32, 5609-5609.	1.6	0
56	Mutational landscape of uterine and ovarian carcinosarcomas.. Journal of Clinical Oncology, 2016, 34, 5589-5589.	1.6	0
57	Challenging Case of Postmenopausal Bleeding and Complete Urogenital Duplication. American Journal of Case Reports, 2016, 17, 331-336.	0.8	0
58	Combination of triapine, olaparib, and cediranib for epithelial ovarian cancer therapy.. Journal of Clinical Oncology, 2018, 36, e17551-e17551.	1.6	0
59	The incidence of microscopic adnexal metastatic disease in women with presumed early stage endometrial cancer.. Journal of Clinical Oncology, 2019, 37, e17128-e17128.	1.6	0